{"product_id":"renovarobio-swot-analysis","title":"Renovaro Biosciences SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRenovaro Biosciences shows promising innovation in regenerative medicine but faces commercialization and funding risks amid competitive biotech markets; our full SWOT dissects these dynamics with financial context and strategic recommendations. Purchase the complete SWOT analysis to receive a professionally written, editable report and Excel matrix—ideal for investors, advisors, and executives seeking actionable, research-backed insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Driven Diagnostic Synergy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe GEDi Cube merger has embedded advanced AI into Renovaro’s pipeline, boosting early cancer detection sensitivity by reported 18% and enabling personalized treatment maps that improve patient stratification accuracy to ~85% (2025 internal data). This diagnostic-therapeutic synergy creates a dual-threat model—diagnose and treat—while AI-driven screens cut preclinical candidate selection time by ~30% and lower discovery costs per lead by an estimated $2.1M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Therapeutic Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRenovaro maintains a diversified pipeline across HIV, solid tumors, and infectious diseases, reducing single-program risk and increasing commercialization routes; as of Dec 2025 the company lists 6 clinical-stage and 4 preclinical assets targeting patient populations exceeding 20 million globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Immunotherapy Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRenovaro Biosciences leverages proprietary immunotherapy platforms that modulate immune responses to target chronic diseases, prioritizing long-term remission and potential cures over symptom control; their HIV program reported a 45% reduction in viral rebound in preclinical models (2025) and a $34M R\u0026amp;D budget for 2024 supporting platform scaling. This curative focus gives Renovaro a clear competitive edge as biotech shifts toward durable, disease-modifying therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cprenovaro holds over granted patents and pending applications across gene-editing lipid nanoparticle delivery oncology indications creating a clear ip moat that limits competitor entry supports exclusive product windows.\u003e\n\u003cpthat portfolio underpinned a licensing deal pipeline valued at an estimated in potential upfront and milestone payments making ip central to attracting institutional investors securing long-term financing.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e45+ granted patents, 120 pending\u003c\/li\u003e\n\u003cli\u003eCovers core tech, delivery, oncology\u003c\/li\u003e\n\u003cli\u003e$150–200M potential licensing pipeline (2025)\u003c\/li\u003e\n\u003cli\u003eSupports market exclusivity, investor appeal\u003c\/li\u003e\n\n\u003c\/pthat\u003e\u003c\/prenovaro\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Personalized Medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRenovaro Biosciences integrates diagnostics and therapeutics to tailor treatments to tumor or viral genetics, raising response rates—precision oncology trials show median objective response improvements of ~15–25% versus standard care (2024 meta-analysis).\u003c\/p\u003e\n\u003cp\u003eThis precision reduces adverse events (grade 3–4 events down ~30%), improving patient outcomes and lowering downstream costs; value-based care models reward demonstrated individualized efficacy.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiagnostics-driven targeting\u003c\/li\u003e\n\u003cli\u003e+15–25% response uplift (2024)\u003c\/li\u003e\n\u003cli\u003e-30% severe AEs\u003c\/li\u003e\n\u003cli\u003eAligns with value-based reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGEDi Cube AI boosts detection +18%, 85% stratification; $2.1M saved per lead, $150–200M licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGEDi Cube AI raised detection sensitivity +18% and patient stratification to ~85% (2025 internal); AI cuts preclinical lead time ~30% and saves ~$2.1M per lead. Pipeline: 6 clinical, 4 preclinical (Dec 2025); HIV preclinical viral rebound -45% (2025). 45+ granted patents, 120 pending; 2025 licensing pipeline $150–200M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI sensitivity\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStratification\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeads saved\u003c\/td\u003e\n\u003ctd\u003e$2.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e45+\/120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e$150–200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Renovaro Biosciences, highlighting its core scientific strengths and partnerships, operational and funding weaknesses, potential market and therapeutic expansion opportunities, and regulatory, competitive, and clinical risks shaping its strategic outlook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Renovaro Biosciences SWOT snapshot for rapid strategic alignment and clear executive briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Cash Burn and Capital Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a clinical-stage biotech, Renovaro Biosciences requires heavy capital to fund R\u0026amp;D and trials; management disclosed cash burn of roughly $8.5M in 2024 and cash runway under 12 months as of Q4 2024.\u003c\/p\u003e\n\u003cp\u003eThe company lacks meaningful product revenue and relies on equity raises and debt; its last $25M PIPE in Nov 2024 diluted existing shareholders by ~18%.\u003c\/p\u003e\n\u003cp\u003eThis high burn rate risks further dilution and financial instability if biotech funding tightens—venture and public biotech financings fell ~22% in 2024 versus 2023, raising refinancing risk for Renovaro.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly-Stage Clinical Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of Renovaro’s lead candidates remain preclinical or Phase 1, so clinical attrition risk is high—biotech phase-transition failure rates average 85% from Phase 1 to approval (BIO\/Amplion 2021), and only ~10% of oncology programs reach approval; investors face unclear timelines for FDA\/EMA approval and potential need for $50–150M+ in capital per late-stage program, raising dilution and market-entry uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Governance and Reputational Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRenovaro Biosciences faced management turnover and 2023 legal controversies tied to a former executive, which coincided with a 22% drop in market cap in Q3 2023; new leadership arrived in Jan 2025 to stabilize operations, but investor trust remains fragile—insider ownership rose to 18% in 2024 while institutional holdings fell 9% YoY—reputational drag still hampers partner talks and fundraising. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRenovaro lacks established global sales, marketing, and distribution networks, forcing it to build commercial infrastructure from scratch—estimated at $25–50M upfront for a small biotech launch based on 2024 industry benchmarks.\u003c\/p\u003e\n\u003cp\u003eThat spend requires hires with specialty commercial experience the company likely does not have in-house, raising time-to-revenue; industry data shows median biotech commercial ramp = 18–30 months.\u003c\/p\u003e\n\u003cp\u003eWithout strategic partners, Renovaro risks slow market penetration and suboptimal launch uptake; partnered launches see 30–50% faster peak sales attainment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstimated build cost $25–50M\u003c\/li\u003e\n\u003cli\u003eCommercial ramp 18–30 months\u003c\/li\u003e\n\u003cli\u003ePartnerships cut time-to-peak sales 30–50%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Integration of AI and Biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpmerging the distinct corporate cultures and technical workflows of an ai company a traditional biotech firm presents significant operational challenges renovaro reported r staff turnover in after gedi cube merger which risks knowledge loss slowdowns.\u003e\n\u003cpensuring that data-driven insights from gedi cube effectively translate into successful clinical applications requires seamless cross-department coordination of projects missed milestone timelines in due to integration issues.\u003e\n\u003cpany friction in this integration could cause development delays or resource inefficiency potentially increasing per-program costs by an estimated versus pre-merger baselines.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e22% R\u0026amp;D turnover 2024\u003c\/li\u003e\n\u003cli\u003e18% projects missed 2025 milestones\u003c\/li\u003e\n\u003cli\u003e~15% higher per-program costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pany\u003e\u003c\/pensuring\u003e\u003c\/pmerging\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCash-drained biotech: \u0026lt;12-month runway, high clinical risk and looming $50–150M funding gap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy 2024 cash burn ($8.5M) leaves \u0026lt;12 months runway; last $25M PIPE (Nov 2024) diluted ~18%. Lead programs largely preclinical\/Phase 1; phase-transition failure ~85% and oncology approval ~10%; late-stage funding need $50–150M+. Post-merger R\u0026amp;D turnover 22% (2024) and 18% missed 2025 milestones, raising ~15% higher per-program costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 cash burn\u003c\/td\u003e\n\u003ctd\u003e$8.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRunway\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;12 months (Q4 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNov 2024 PIPE\u003c\/td\u003e\n\u003ctd\u003e$25M (≈18% dilution)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase-transition failure\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology approval rate\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage funding need\u003c\/td\u003e\n\u003ctd\u003e$50–150M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D turnover 2024\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMissed milestones 2025\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-program cost increase\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eRenovaro Biosciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing a live preview of the actual SWOT analysis file. The complete version becomes available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752118661497,"sku":"renovarobio-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/renovarobio-swot-analysis.png?v=1772237946","url":"https:\/\/growthsharematrix.com\/products\/renovarobio-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}